Publikationen, an denen er mitarbeitet ARTEMIO MOJON OJEA (153)

2024

  1. Clinical trial design for assessing hypertension medications: are critical circadian chronopharmacological principles being taking into account?

    Expert Review of Clinical Pharmacology, Vol. 17, Núm. 2, pp. 119-130

  2. Impact of hypertension treatment-time on cardiovascular outcomes: erroneous trial selection leading to suspect findings

    Journal of hypertension, Vol. 42, Núm. 1, pp. 190-191

  3. Risk of heart failure in ambulatory resistant hypertension: a meta-analysis of observational studies

    Hypertension Research, Vol. 47, Núm. 5, pp. 1235-1245

2023

  1. Critical appraisal of recent translational chronopharmacology and chronotherapeutic reviews, meta-analyses, and pragmatic patient trials discloses significant deficiencies of design and conduct and suspect findings

    Chronobiology International, Vol. 40, Núm. 8, pp. 1146-1167

  2. Elevated asleep blood pressure and non-dipper 24h patterning best predict risk for heart failure that can be averted by bedtime hypertension chronotherapy: A review of the published literature

    Chronobiology International, Vol. 40, Núm. 1, pp. 63-82

2022

  1. Consideration of nondipping heart rate during ambulatory blood pressure monitoring to improve cardiovascular risk assessment. Response

    Revista Espanola de Cardiologia

  2. Ingestion-time differences in the pharmacodynamics of dual-combination hypertension therapies: Systematic review and meta-analysis of published human trials

    Chronobiology International, Vol. 39, Núm. 4, pp. 493-512

2021

  1. Ambulatory blood pressure monitoring-based definition of true arterial hypertension

    Minerva Medica, Vol. 111, Núm. 6, pp. 573-588

  2. Cardiovascular disease risk stratification by the Framigham score is markedly improved by ambulatory compared with office blood pressure

    Revista Espanola de Cardiologia, Vol. 74, Núm. 11, pp. 953-961

  3. Extent of asleep blood pressure reduction by hypertension medications is ingestion-time dependent: Systematic review and meta-analysis of published human trials

    Sleep Medicine Reviews, Vol. 59

  4. Guidelines for the design and conduct of human clinical trials on ingestion-time differences–chronopharmacology and chronotherapy–of hypertension medications

    Chronobiology International, Vol. 38, Núm. 1, pp. 1-26

  5. Ingestion-time differences in the pharmacodynamics of hypertension medications: Systematic review of human chronopharmacology trials

    Advanced Drug Delivery Reviews, Vol. 170, pp. 200-213

  6. Lowering Nighttime Blood Pressure With Bedtime Dosing of Antihypertensive Medications: Controversies in Hypertension - Pro Side of the Argument

    Hypertension, Vol. 78, Núm. 3, pp. 879-893

  7. Systematic review and quality evaluation of published human ingestion-time trials of blood pressure-lowering medications and their combinations

    Chronobiology International, Vol. 38, Núm. 10, pp. 1460-1476

2020

  1. Ambulatory blood pressure-based inclusion criteria in the Hygia Chronotherapy Trial. Rebuttal to Lemmer and Middeke

    Chronobiology International, Vol. 37, Núm. 8, pp. 1270-1272

  2. Bedtime hypertension chronotherapy best reduces cardiovascular disease risk as corroborated by the Hygia Chronotherapy Trial. Rebuttal to European Society of Hypertension officials.

    Chronobiology International, pp. 1-10

  3. Bedtime hypertension chronotherapy best reduces cardiovascular disease risk as documented by MAPEC and Hygia Chronotherapy outcomes trials

    Chronobiology International, pp. 1-8

  4. Bedtime hypertension treatment improves cardiovascular risk reduction: the Hygia Chronotherapy Trial

    European heart journal, Vol. 41, Núm. 48, pp. 4565-4576

  5. Chronotherapy of hypertension, asleep ambulatory blood pressure, and glaucoma

    European Heart Journal

  6. Chronotherapy of hypertension: advantages of 48-h ambulatory blood pressure monitoring assessments in MAPEC and Hygia Chronotherapy Trial

    Chronobiology International, pp. 1-12